LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY

LSKB TO REPORT NON-CLINICAL RIVOCERANIB (APATINIB) COMBINATION WITH IMMUNOTHERAPY

SALT LAKE CITY, April 16, 2018 – LSK BioPharma (LSKB) today will present a poster at the American Association for Cancer Research (AACR) Annual Meeting in Chicago. The poster discloses nonclinical data suggesting a synergistic combination of rivoceranib (apatinib) with anti-PD-1 therapy. The combination significantly improved tumor growth suppression over each agent in monotherapy in a lung cancer mouse model study. These results are encouraging for ongoing and upcoming human clinical trials of rivoceranib in combination with the anti-PD-1 therapies nivolumab and pembrolizumab (NCT03396211, NCT03407976).

The poster can be found at: http://lskbiopharma.com/aacr-2018/

About Rivorceranib (Apatinib)

Rivorceranib is the first successful small-molecule angiogenesis inhibitor in gastric cancer. It was approved in China (advanced gastric cancer, Dec 2014) by the Chinese-territory license-holder Jiangsu Hengrui. LSK BioPharma, which holds the global rights (ex-China), has initiated a global phase 3 pivotal trial in gastric cancer. The Company also plans to initiate additional studies in earlier lines of gastric cancer treatment as well as in other solid tumors. LSKB has partnered development and marketing in Korea with Bukwang Pharma. Rivorceranib acts by inhibiting angiogenesis in solid tumors. Angiogenesis is a critical process in cancer growth and proliferation, as tumors cannot grow beyond 1–2mm3 without sufficient blood supply. Rivorceranib acts by selectively inhibiting VEGFR-2 which is primarily responsible for tumor-mediated angiogenesis. Rivorceranib has been tested in almost 1,000 patients worldwide and has demonstrated efficacy in numerous cancers including gastric cancer, colorectal cancer, HCC, NSCLC, breast cancer, mesothelioma, and neuroendocrine tumors.

About LSK BioPharma

LSKB is a privately-held biopharmaceutical company based in Salt Lake City, Utah. The Company specializes in the early clinical development of promising therapies for unmet medical needs in cancer. LSKB is developing two exciting drug candidates; a small molecule angiogenesis inhibitor with potential to treat a variety of solid tumors and a BTK/JAK3 inhibitor with the potential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent. LSKB can be found on the web at www.lskbiopharma.com.

Contact:
Angie Price
angieprice@lskbiopharma.com

###